1. Home
  2. NRK vs ABUS Comparison

NRK vs ABUS Comparison

Compare NRK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New York AMT-Free Quality Municipal Income Fund

NRK

Nuveen New York AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$10.42

Market Cap

888.1M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.17

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRK
ABUS
Founded
2002
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
888.1M
888.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NRK
ABUS
Price
$10.42
$4.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
187.3K
2.1M
Earning Date
01-01-0001
03-26-2026
Dividend Yield
4.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,606,000.00
Revenue This Year
N/A
$125.30
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
116.64
52 Week Low
$8.95
$2.71
52 Week High
$11.09
$5.10

Technical Indicators

Market Signals
Indicator
NRK
ABUS
Relative Strength Index (RSI) 73.20 48.44
Support Level $10.19 $3.85
Resistance Level $10.29 $4.26
Average True Range (ATR) 0.05 0.33
MACD 0.01 0.02
Stochastic Oscillator 100.00 58.18

Price Performance

Historical Comparison
NRK
ABUS

About NRK Nuveen New York AMT-Free Quality Municipal Income Fund

Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: